TRIM33 and cancer: To further explore immunoreactivity, we used the new assay containing only the N-terminus region of TIF1γ and the results showed a high levels on immunoreactivity regardless of cancer and non-cancer status of the anti-TIF1γ seropositive patients (Figure 3b–c).